



CASE LA0112 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jonathan N. Provoost

Type or print name

Signature

May 10, 2004

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GUNGOR ET AL.

APPLICATION NO: 10/775,742

FILED: FEBRUARY 10, 2004

FOR: NOVEL THIAZOLIDINE COMPOUNDS AS CALCIUM SENSING
RECEPTOR MODULATORS

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Jonathan N. Grovoost
Attorney for Applicants
Reg. No. 44,292

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3816

Date: May 10, 2004

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0112 NP
APPLICATION NO.
10/775,742
APPLICANT
GUNGOR ET AL.
FILING DATE
FEBRUARY 10, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,411,890	10/25/83	Momany			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 89/07110	8/10/89	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 89/07111	8/10/89	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 93/04081	3/4/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Arndt, D., "Mangan-Verbindungen als Oxidationsmittel in der organischen Chemie", Methoden der Organischen Chemie (Houben-Weyl), Fourth Edition, Vol. 4, Part 1b, Georg Thieme Verlag, Stuttgart, publ., Müller, E., ed., pp. 466-672 (1975)
	AS	Betts, M.J. et al., "'Hidden' axial chirality as a stereodirecting element in reactions involving enol(ate) intermediates. Part 2. Cyclisation reactions of methyl (4 <i>R</i>)-3-(2-diazo-3-oxobutanoyl)-1,1-dioxo-1 λ^6 ,3-(and 1-oxo-1 λ^4 ,3-) thiazolidine-4-carboxylates", J. Chem. Soc., Perkin Trans. 1, pp. 1067-1072 (1999)
	AT	Bundgaard, H., Chapter 5: "Design and Application of Prodrugs", A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0112 NP
APPLICATION NO.
10/775,742
APPLICANT
GUNGOR ET AL.
FILING DATE
FEBRUARY 10, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents)
2AB	Cagniant, P. et al., "No. 50. Sur la synthèse de quelques amines arylaliphatiques dérivées du β -méthyl-naphtalène", Bull. Soc. Chim. Fr., pp. 349-353 (1943)
2AC	Edwards, J.P. et al., "Nonsteroidal Androgen Receptor Agonists Based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one", Bioorganic & Medicinal Chemistry Letters, Vol. 9, pp. 1003-1008 (1999)
2AD	Florvall, L. et al., "Selective Monoamine Oxidase Inhibitors. 3. Cyclic Compounds Related to 4-Aminophenethylamine. Preparation and Neuron-Selective Action of Some 5-(2-Aminoethyl)-2,3-dihydroindoles", J. Med. Chem., Vol. 29, No. 8, pp. 1406-1412 (1986)
2AE	Gowen, M. et al., "Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats", The Journal of Clinical Investigation, Vol. 105, No. 11, pp. 1595-1604 (2000)
2AF	Greene, T.W. et al., Protecting Groups in Organic Synthesis, Third Edition, John Wiley & Sons, Inc., publ. (1999) (table of contents)
2AG	Greenstein, J.P. et al., Chemistry of the Amino Acids, Vol. 3, Robert E. Krieger Publishing Company, Inc., publ., pp. v-xiii (table of contents) (1984)
2AH	Hamann, L.G. et al., "Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)", J. Med. Chem., Vol. 42, pp. 210-212 (1999)
2AI	Lee, D.G., Chapter 11: "Phase Transfer Assisted Permanganate Oxidations", Oxidation in Organic Chemistry, Part D, Academic Press, publ., Trahanovsky, W.S., ed., pp. 147-204 (1982)
2AJ	Moed, H.D. et al., "Synthesis of β -phenyl-ethylamine Derivatives. III) Bronchodilators", Recl. Trav. Chim. Pays-Bas, Vol. 74, pp. 919-936 (1955)
2AK	Neer, R.M. et al., "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis", The New England Journal of Medicine, Vol. 344, No. 19, pp. 1434-1441 (2001)
2AL	Nichols, D.E. et al., "Effects of Certain Hallucinogenic Amphetamine Analogues on the Release of [3 H]Serotonin from Rat Brain Synaptosomes", J. Med. Chem., Vol. 25, No. 5, pp. 530-535 (1982)
2AM	Norris, R.K. et al., "Kinetics and Stereochemistry of Elimination of Nitrous Acid from 1-p-Nitrophenyl-2-nitroethyl Derivatives", Aust. J. Chem., Vol. 39, pp. 281-294 (1986)
2AN	Stewart, R., Chapter 1: "Oxidation by Permanganate", Oxidation in Organic Chemistry, Part A, Academic Press, publ., Wiberg, K.B., ed., pp. 1-68 (1965)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0112 NP
APPLICATION NO.
10/775,742
APPLICANT
GUNGOR ET AL.
FILING DATE
FEBRUARY 10, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	3AA	Wermuth, C.G. et al., Chapter 31: "Designing Prodrugs and Bioprecursors I: Carrier Prodrugs", The Practice of Medicinal Chemistry, Academic Press, publ., Wermuth, C.G., ed., pp. 671-696 (1996)
	3AB	Whitfield, J.F. et al., "Parathyroid Hormone, Its Fragments and Their Analogs for the Treatment of Osteoporosis", Treat. Endocrinol., Vol. 1, No. 3, pp. 175-190 (2002)
	AC	
	AD	
	AE	
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.